Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

Autor/a

Sinnollareddy, Mahipal

Sousa, Eduardo

Soy Muner, Dolors

Spring, Anna

Starr, Therese

Stephens, Dianne

Taccone, Fabio Silvio

Thomas, Jane

Turnidge, John

Valkonen, Miia

De Waele, Jan J.

Varghese, Julie M.

Deans, Renae

Wallis, Steven C.

Donnellan, Sine

Walker, Robert J.

Eastwood, Glenn M.

Williams, Tricia

Frey, Otto R.

Wilson, Luke C.

Goutelle, Sylvain

Wittebole, Xavier

Gresham, Rebecca

Ain Jamal, Janattul

Joynt, Gavin M.

Kanji, Salmaan

Roberts, Jason A.

Ulldemolins, Marta

Liu, Xin

Baptista, João P.

Bilgrami, Irma

Boidin, Clement

Brinkmann, Alexander

Castro, Pedro

Choi, Gordon

Cole, Louise

Wright, Daniel F.B.

Zikou, Xanthi T.

Bellomo, Rinaldo

Lipman, Jeffrey

Kluge, Stefan

König, Christina

Koulouras, Vasilios P.

Lassig-Smith, Melissa

Laterre, Pierre-Francois

Lee, Anna

Lefrant, Jean-Yves

Lei, Katie

Leung, Patricia

Llauradó Serra, Mireia

Martín Loeches, Ignacio

Mat Nor, Mohd Basri

Mudaliar, Yugan

Ostermann, Marlies

Paul, Sanjoy K.

Peake, Sandra L.

Rello, Jordi

Roberts, Darren M.

Roberts, Michael S.

Richards, Brent

Rodríguez, Alejandro

Roehr, Anka C.

Roger, Claire

Seoane, Leonardo

Data de publicació

2025-12-03T16:43:52Z

2025-12-03T16:43:52Z

2025-08-13

2025-12-03T16:43:52Z



Resum

Purpose: Optimal dosing of meropenem and piperacillin/tazobactam in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to variable pharmacokinetics. We aimed to develop generalisable optimised dosing recommendations for these antibiotics. Methods: Prospective, multinational pharmacokinetic study including patients requiring various forms of RRT. Independent population PK models were developed, externally validated and applied to perform Monte Carlo dosing simulations using Monolix and Simulx. We calculated the probability that these dosing regimens achieved standard and high therapeutic unbound antibiotic concentrations over 100% of the dosing interval for the treatment of Enterobacterales and Pseudomonas aeruginosa. Results: We enrolled 300 patients from 22 intensive care units across 12 countries receiving continuous veno-venous haemodialysis (13.0%), haemofiltration (23.3%), haemodiafiltration (48.4%) or sustained low-efficiency dialysis (15.3%). Models were developed using data from 234 patients (8322 samples) and validated with 66 additional patients (560 samples). Predictive performance was high, with mean prediction errors of - 5.2% for meropenem and - 16.9% for piperacillin. Dosing simulations showed that meropenem and piperacillin/tazobactam dosing requirements were dependent on urine output and RRT intensity and duration (p < 0.05). In all scenarios, extended/continuous infusions led to a better achievement of effective concentrations with lower daily doses compared to short infusion. Dosing nomograms were developed to inform dosing for different RRT settings, urine outputs, and target concentrations. Conclusion: RRT intensity and duration and urine output determine meropenem and piperacillin/tazobactam dosing requirements in critically ill patients receiving RRT. Extended/continuous infusions facilitate the attainment of effective concentrations.

Tipus de document

Article
Versió publicada

Llengua

Anglès

Matèries i paraules clau

Unitats de cures intensives; Malalts en estat crític; Medicaments antibacterians; Intensive care units; Critically ill; Antibacterial agents

Publicat per

Springer Verlag

Documents relacionats

Reproducció del document publicat a: https://doi.org/10.1007/s00134-025-08067-w

Intensive Care Medicine, 2025, vol. 51, num.9, p. 1628-1640

https://doi.org/10.1007/s00134-025-08067-w

Drets

cc by-nc (c) Sinnollareddy, Mahipal et al., 2025

https://creativecommons.org/licenses/by-nc/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)